In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


More positive safety results for NewLink/Merck Ebola vaccine

This article was originally published in Scrip

Executive Summary

Yet another study has shown an experimental Ebola vaccine from NewLink Genetics and its partner Merck to be safe, with the product eliciting robust antibody responses in all 40 of the healthy adults who received it at Walter Reed Army Institute of Research in Silver Spring, Maryland and at the National Institutes of Health (NIH) in Bethesda, Maryland.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts